FDA Reverses Course On Fecal Transplant Requirement

Law360, New York (July 19, 2013, 6:47 PM EDT) -- The U.S. Food and Drug Administration on Thursday backed away from a short-lived requirement that doctors submit reams of data before using promising new fecal transplants to eradicate antibiotic-resistant infections, saying it recognized the mandate would be impractical and not in patients’ best interests.

In a guidance document, the FDA said that despite a lack of clinical studies showing effectiveness, it wouldn’t block uses of fecal microbiota — healthy bacteria — to treat tough cases of clostridium difficile, a bacterium that can cause severe diarrhea and...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.